![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2007 Falk et al; licensee BioMed Central Ltd. Electroporation of cDNA/Morpholinos to targeted areas of embryonic CNS in Xenopus 1Department of Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge CB2 3DY, UK 2The Queensland Brain Institute, The University of Queensland, St Lucia, QLD, 4072, Australia Corresponding author.Julien Falk: jf348/at/cam.ac.uk; Jovana Drinjakovic: jd329/at/cam.ac.uk; Kin Mei Leung: kml26/at/cam.ac.uk; Asha Dwivedy: ad227/at/cam.ac.uk; Aoife G Regan: Aoife.Regan/at/ncri.org.uk; Michael Piper: m.piper/at/uq.edu.au; Christine E Holt: ceh/at/mole.bio.cam.ac.uk Received June 8, 2007; Accepted September 27, 2007. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC.Abstract Background Blastomere injection of mRNA or antisense oligonucleotides has proven effective in analyzing early gene function in Xenopus. However, functional analysis of genes involved in neuronal differentiation and axon pathfinding by this method is often hampered by earlier function of these genes during development. Therefore, fine spatio-temporal control of over-expression or knock-down approaches is required to specifically address the role of a given gene in these processes. Results We describe here an electroporation procedure that can be used with high efficiency and low toxicity for targeting DNA and antisense morpholino oligonucleotides (MOs) into spatially restricted regions of the Xenopus CNS at a critical time-window of development (22–50 hour post-fertilization) when axonal tracts are first forming. The approach relies on the design of "electroporation chambers" that enable reproducible positioning of fixed-spaced electrodes coupled with accurate DNA/MO injection. Simple adjustments can be made to the electroporation chamber to suit the shape of different aged embryos and to alter the size and location of the targeted region. This procedure can be used to electroporate separate regions of the CNS in the same embryo allowing separate manipulation of growing axons and their intermediate and final targets in the brain. Conclusion Our study demonstrates that electroporation can be used as a versatile tool to investigate molecular pathways involved in axon extension during Xenopus embryogenesis. Electroporation enables gain or loss of function studies to be performed with easy monitoring of electroporated cells. Double-targeted transfection provides a unique opportunity to monitor axon-target interaction in vivo. Finally, electroporated embryos represent a valuable source of MO-loaded or DNA transfected cells for in vitro analysis. The technique has broad applications as it can be tailored easily to other developing organ systems and to other organisms by making simple adjustments to the electroporation chamber. Background Xenopus laevis is a model system widely used to study vertebrate development. Much of our understanding of early embryo patterning and tissue induction has come from this model, and Xenopus has provided many important insights into neuronal development. However, many of the molecules involved in neuronal differentiation also play crucial roles in early development [1,2]. Therefore, the classical approach of injecting blastomeres with DNA/mRNA or antisense oligonucleotides (morpholinos, MOs) is of limited use for studying axon guidance as it interferes with gene function during early development and frequently leads to abnormal embryogenesis. In some cases, this problem can be circumvented by the use of inducible or tissue specific promoters [3-6] but selective expression during a specific time-window in selected populations of cells remains difficult and levels of expression often decrease with time due to plasmid dilution during cell division [7,8]. Ideally, to test the function of a specific molecule in axon guidance, its function should be disrupted exclusively during the period of axonogenesis. To this end, lipofection has proven useful to introduce DNA in the developing eye and brain of stage 19–24 Xenopus embryos [8,9] and viral infection using vaccina virus has also been used in stage 40–48 Xenopus embryos [10,11]. However, each of these techniques has drawbacks, such as the low efficiency of transfection of lipofection and the low expression level and reproducibility of vaccinia viral infection [12]. Electroporation does not suffer from these limitations. Indeed, its ease of use combined with efficient and accurate spatio-temporal targeting quickly established electroporation as superior to most other methods of genetic manipulations in chick embryos [13-16]. In addition to DNA and RNA, electroporation can be used to deliver dsRNA, RNAi, antisense morpholinos (MO), dyes and proteins [17-21]. This large repertoire and the ability to introduce several types of molecules at the same time have provided new paradigms for monitoring gene expression, cell morphology, movements and lineage, as well as efficient means for interfering with protein and microRNA function [13,19,22-25]. As a result, chick electroporation has made major contributions to the understanding of gene regulation, cell proliferation, migration and differentiation, and more generally of the underlying mechanism of nervous system patterning and neuronal wiring [13,22,26-28]. Electroporation methods have now been adapted for use in many animal models including mouse [13,29], rat [29], zebrafish [30,31], ascidian [32], hydra [33] and drosophila [34]. In Xenopus, electroporation has been successfully used to introduce DNA into the brains of late tadpole embryos (stages 44–48) [10,12,35] and RNA into the CNS of early neurula embryos (stage 12.5) [36,37]. Although a previous study reports that stage 25–29/30 embryos can be successfully electropermeablized [38], electroporation has only been used during this developmental window to enhance lipofection [39]. Thus, no electroporation protocol has been described for the intermediate developmental ages (stages 21–40) that span the critical 40 h window of brain wiring, when most of the major axon tracts are formed in the Xenopus CNS [40-44]. We describe here a detailed electroporation procedure to introduce efficiently both DNA and MOs to restricted regions of the brain and eye between stages 21 and 35/36. This protocol relies on the design of "electroporation chambers", tailored to individual embryonic stages, which allows reproducible and efficient large or targeted electroporation of different regions of the CNS. We demonstrate that projection neurons and their targets, both intermediate and final, can be selectively manipulated by multiple targeted electroporations or a combination of electroporation and lipofection. As such, electroporation can be a reliable and efficient tool to examine gene function during CNS differentiation. Finally, we provide evidence of the potential benefits of electroporation for the study of axonogenesis in vitro. Results and discussion Electroporation chambers enable reproducible and efficient electroporation Efficient and reproducible electroporation relies primarily on the precision of the injection of DNA. To control injection accuracy, stage 21–35/36 embryos must be held in the desired position and submerged in a drop of medium, as they easily deform and are highly sensitive to drying. Previously published electroporation procedures could not be used because they do not permit accurate orientation of the embryos [38] nor take into account the soft-tissue vulnerability or morphology of the targeted stages [12,36]. Therefore, we developed electroporation chambers tailored individually to the size and morphology of embryos from stages 21 to 35/36. The basic design of the chambers consists of two channels carved perpendicular to one another in Sylgard in the shape of a cross (Figure (Figure1a).1a
Electroporation leads to efficient transfection in Xenopus To determine the optimal conditions for Xenopus electroporation, voltage, frequency and duration of electrical pulses were systematically varied using the experimental set-up illustrated in Figure Figure1a1a To further characterize the efficiency of electroporation, nucleus-targeted GFP (nls-GFP) was transfected to quantify the fraction of GFP-expressing versus non-expressing cells on transverse brain sections counterstained with a nuclear stain (DAPI). 48 h after electroporation (20 V/50 ms/1 s/8 x), the average fraction of cells expressing GFP per section was 47.1 ± 2.5% in the transfected region (n = 47 sections 6 embryos; Figure Figure1e1e
Finally, we assayed the potential adverse side effects of electroporation. Electroporation did not increase either the embryo death rate or the occurrence of morphological abnormalities, provided the pulse voltage remained under 25 V and the pulse duration under 100 ms (Figure (Figure1d1d Electroporation at different stages produces rapid and long-lasting transgene expression Neuronal differentiation and initial establishment of the major axonal projections progress rapidly from stage 20 to 40 and, during this period, the neuroepithelium undergoes major reorganization with post-mitotic neurons migrating away from the ventricular surface to the superficial layers. To achieve fine temporal resolution, the electroporation procedure should be similarly efficient across different time-windows. Therefore, we compared the efficiency of the electroporation protocol over different stages. Embryos were electroporated following intraventricular pCS2GFP-DNA injection at stages ranging from 21 to 35/36 in chambers specially adapted to their morphology. External inspection of embryos under the fluorescent strereomicroscope showed that the fraction of embryos exhibiting bright GFP expression 12 h after electroporation was >70%, regardless of the stage at which the electroporation was performed. Despite these similar levels at a gross level, analysis of the GFP positive cell fraction (nls-GFP) on transverse sections revealed that a sharp decrease in efficiency occurs at stage 32 (Figure (Figure3a).3a
In order to gain access to the cells situated close to the pia, we delivered DNA to the pial surface by injecting under the skin epidermis instead of intraventricularly (stage 29/30 embryos). Subcutaneous injections, followed immediately by electroporation, efficiently and selectively transfected cells in superficial layers of the brain (Figure (Figure3e3e Overall, GFP expression in embryos electroporated between stages 21 to 35/36 displayed similar kinetics. In whole embryos, the GFP signal can first be detected 5–6 h after electroporation. This signal progressively intensifies and spreads over the subsequent 36 h, and remains high for several days. Nuclear GFP was used to quantify the GFP expression at different time points on transverse sections of embryos electroporated at stage 29/30. A progressive increase in both the fraction and the average intensity of the GFP positive cells was observed between 6 and 48 h post-electroporation (Figure 3f–h Controlling spatial targeting to study axon guidance: the retino-tectal projection The spatial selectivity allowed by electroporation has proven useful for axon guidance studies [17,23,48-51]. Thus, using the well-characterized retinotectal projection system, we next asked if our procedure could enable selective transfection of retinal ganglion cells (RGCs) and/or the regions through which their axons travel. Normally, axons from RGCs exit the eye, travel along the optic nerve to enter the brain at the ventral diencephalon. After crossing the midline at the optic chiasm, they extend dorsally through the optic tract in the diencephalon before turning caudally to reach the optic tectum, where they arborize and form synapses. Since only the region lying between the two electrodes is efficiently electroporated, different areas can be selectively electroporated by sliding the embryo forward or backward in the main channel to expose the rostral or caudal part of the head (Figure (Figure4a4a
To specifically electroporate the eye, embryos were placed belly up so that the eye, but not the brain, was aligned with the electrodes (Figure (Figure4j).4j Finally, we asked if both the eye and the pathway where retinal axons grow (e.g. optic tract, optic tectum) could be manipulated separately within the same embryo. We electroporated eyes at stage 24 with GAP-RFP and brains 8 h later at stage 30 with GAP-GFP. We found that dual-electroporation produced specific expression both within the eye and pathway. Importantly, dual electroporation did not decrease embryo viability or cause abnormal development (n = 21), and did not affect brain anatomy (see additional file 2ee). Furthermore, eye-specific electroporation can be combined with either large or area-specific brain electroporation (Figure 5a–d
Targeted loading of antisense morpholinos by electroporation In addition to DNA transfection, intracellular delivery of antisense morpholinos (MOs) was tested. MOs are an effective tool to knock-down protein expression in Xenopus through blastomere injection [53,54] but their inability to be taken up through the plasma membrane has limited their use at late stages. Standard MOs are uncharged and, therefore, cannot be electroporated. However, MOs can be fluorescently tagged for visualization and, fortuitously, the tag introduces a charge making them amenable to electroporation [19]. Electroporation of MOs in chick has been used to study nervous system development, and single cell electroporation in the brain of late-stage Xenopus embryos has been reported [12,19]. Lissamine-tagged MOs were electroporated into both the brains and the eyes of stage 22 to 33/34 embryos with a success rate of over 80% with all four settings used (20 V/50 ms/1 s/8 x, 18 V/50 ms/1 s/10 x, 18 V/25 ms/1 s/10 × or 15 V/50 ms/1 s/10 x). In transverse sections, MO-loaded cells were evenly distributed throughout the width of the electroporated side of neuroepithelium, and along most of its dorso-ventral axis (Figure (Figure6a6a
Plasmids were also successfully co-electroporated with negatively charged MOs (both fluorescein- and special delivery lissamine-tagged) (Figure 6e–g At a cellular level, electroporated MOs seem to diffuse evenly around the cytosol and into the nucleus. Although short neuronal processes could be visualized with the MO fluorescence, longer processes were usually so weakly labeled that they were difficult to follow. However, co-transfection with GAP-GFP highlighted axons emanating from the electroporated RGCs, making monitoring of axons from MO-loaded cells feasible (Figure (Figure6g6g Finally, we took advantage of the high co-electroporation efficiency to test the ability of the loaded MO to down-regulate translation of its target mRNA. A pCS2 plasmid encoding GFP was electroporated with or without a MO designed to block GFP expression [55]. Using this MO directed against the pCS2+ and cytoplasmic GFP sequences flanking the GFP start codon, we observed a 4-fold decrease of the GFP signal both in the eye and the brain when the MO against GFP was co-electroporated with pCS2GFP (n = 24, n = 30 respectively, data not shown). However, this decrease could be due to biased electroporation and/or nonspecific effects of the anti-GFP MO (such as cell death or general translation inhibition). To rule out such problems, the experiments were performed on the targetable (pCS2) and non-targetable GFP (pEGFP) in the presence of a control tagged MO to assess the electroporation efficiency. Co-electroporation of the GFP MO only decreased the expression of the targetable plasmid (Figure 6h–j In vivo electroporation provides source of transfected/MO-loaded neurons for in vitro studies The embryonic Xenopus brain is extremely small, posing challenges for obtaining a sufficiently large number of cells to perform dissociated cell electroporation protocols [56,57] and alternative transfection methods have low efficiencies [58]. For example, MO uptake by Xenopus retinal cultures is inefficient even when specific transmembrane trafficking molecules, such as Endo-Porter (GeneTools) are used (data not shown). Thus, most Xenopus transfected or MO-loaded cells used in culture have been obtained from embryos injected at early blastomere stages [59]. However, premature death or abnormalities of injected embryos limit the spectrum of MOs or constructs that can be used to analyze later events in vitro. Therefore, we cultured explants or dissociated cells from different parts of brains electroporated with GAP-GFP DNA and/or fluorescently tagged control MOs (fore-, mid- or hind-brain). As shown in Figure 6n–q Conclusion We describe here an optimized procedure to electroporate different brain regions and the eye from stage 21 to 35/36 Xenopus embryos. Both MOs and DNA were delivered with high efficiency and with limited side effects. Electroporation enables both over-expression and knock-down studies to be performed in a spatiotemporally controlled manner. Furthermore, the high co-electroporation (DNA-DNA or DNA-MO) efficiency makes perturbation of several genes feasible and could be useful for identifying and monitoring events in the MO or DNA electroporated cells such as pathfinding or axon branching analysis. In addition, MO-DNA co-electroporation enables "rescue" experiments to be performed. Finally, using different electroporation protocols or DNA concentrations, expression levels can be kept low enough to avoid mis-localization and/or toxicity of over-expressed markers, or maximized to reach efficient concentration of dominant-negative proteins. The electroporation chambers we designed confer several advantages. First, they enable a large number of embryos to be electroporated rapidly in a reproducible way (1–3 min per embryo). Chambers can be readily made to fit embryos of different ages, and appropriate placement of the embryo within the chamber allows different parts of the developing nervous system to be targeted. Furthermore, chambers can also be made to accommodate zebrafish embryos for which electroporation protocols have been recently developed (see additional file 2a–ca-c) [30,31]. Thus, our method has a wide range of prospective applications, both in Xenopus and in other organisms. Indeed, targeting of various other regions of interest for axon guidance (telencephalon, spinal cord) and double brain-targeted electroporations were successfully performed (see additional file 2d–id-i). One main advantage of our protocol is that electroporation can be controlled spatiotemporally, which means that secondary defects arising from early gene manipulations can be avoided. Indeed, the present protocol provides the degree of targeting precision (around 150 μm2) required to selectively electroporate eye or brain regions in Xenopus embryos. As electroporation efficiency remained high at all the stages tested, the described parameters can be used to investigate gene function at a critical time for nervous system development. Electroporation also leads to quicker detectable expression of the DNA than most available techniques [9,11,12]. This rapid onset of transgene expression is particularly useful since in many cases only several hours are needed for an axon to complete its growth. As RNA can be successfully electroporated (data not shown), the delay between electroporation and protein expression could be further shortened. Finally, spatiotemporal control of expression could be further refined by using specific promoters [38]. Lastly, electroporation of previously electroporated or lipofected embryos enables sequential modification of the same region, or a combination of specific modifications of both neurons and the environment through which their axons navigate. The ability to genetically manipulate both the presynaptic neurons and the pathway/targets of their axons in the same embryo will provide a valuable new experimental paradigm for investigating axon-pathway and axon-target interactions in vivo and in vitro. For instance, co-electroporation of suitable makers in double transfected embryos may provide unique insights into the cellular interaction in vivo between axons and the environment, or between axon terminals and their synaptic partners. Methods Animals Oocytes obtained from adult female Xenopus laevis injected with human chorionic gonadotropin hormone (Sigma) were fertilized in vitro. Embryos were raised in 0.1× MBS until they reached the desired stage. Stages were determined according to Nieuwkoop and Faber [60]. Plasmids and Morpholinos Expression plasmids pCS2GAP-GFP and RFP [61,62], pCS2GFP [8,55], pCS2nls-GFP [63], pEGFP (Clontech) were prepared from Escherichia Coli cultures using the Qiagen Midi DNA preparation kit (Qiagen) and resuspended in water. When concentrations above 3 μg/μl were required, the plasmid preparations were concentrated by isopropanol precipitations. Morpholino oligonucleotide paired to a complementary carrier DNA (Special Delivery) directed against the pCS2GFP was a gift from M. Perron [55]. Crude and Special Delivery standard control (Ctr) MOs (5'CCTCTTACCTCA-GTTACAATTTATA3') fluorescently tagged with lissamine (liss) or carboxyfluorescein were purchased from GeneTools. 1 mM stock solutions were prepared and stored at -20°C. Stock solutions were heated at 65°C for 5 min prior to dilution. Electroporation chamber The electroporation chambers consist of two intersecting channels carved in the shape of a "†" in a 0.8 cm layer of silicon elastomer coating the bottom of a 35 mm plastic petri dish (Sylgard 184, Dow Corning, USA) (see additional file 3). This material (Sylgard) was preferred over others by virtue of its mechanical resilience and electrical resistance. Sylgard is sufficiently stable to allow repetitive use of the chamber and soft enough to ensure that embryos are not damaged when placed carefully into the chamber. A total of 8 out of 34 chambers originally tested were selected. The selected chambers were successfully reproduced from negative imprints of the original ones and copies can be provided upon request (see additional file 3). The geometry of the chamber varies depending on the stage and targeting (see additional file 4a). For stage 28–30 embryos, the longitudinal channel is 7 mm long, 1 mm wide and has a maximal depth of 1 mm. The transverse channel, at the ends of which electrodes should be placed, is 4 mm long, 0.8 mm wide and 0.2–0.5 mm deep. Electroporation Protocol Embryos had their vitelline membrane removed and were placed in fresh 0.1× MBS before being anaesthetized in the electroporation medium (0.4 mg/ml MS222 in 1× MBS or 1× MMR). 1× MMR: 100 mM NaCl/2 mM KCl/1 mM MgSO4/2 mM CaCl2/5 mM Hepes/1 mM EDTA. 1× MBS: 88 mM NaCl/1 mM KCl/2.4 mM NaHCO3/10 mM Hepes/0.8 mM MgSO4/0.33 mM Ca(NO3)2/0.4 mM CaCl2. Anaesthetized embryos were individually transferred into the transfection chamber in a drop of medium, placed into the main channel of the chamber and excess medium was gently removed. Homemade flat-ended 0.5 mm wide platinum electrodes (Sigma, 26788-1G, see additional file 4b and 4c) were placed into the transverse channel. Pulled borosilicate glass capillaries (1 mm OD-0.78 ID, GC100TF10, Harvard Apparatus; puller Pul-1, World Precision instrument) were back-filled with MO (0.1–0.5 mM in water) and/or DNA solutions (0.5–2.5 μg/μl in water). In the case of the subcutaneous injections, higher DNA concentrations were used (3–6 μg/μl). In some cases, methylcellulose was added to limit the diffusion of the injected solution and to increase the targeting [46]. Fast Green was added to DNA but not to MO solutions as it has been shown to inhibit MO electroporation [19]. The injection capillary tip was positioned so that the targeted region lay inbetween the tip and the positive electrode. Depending on the stage, 100–300 nl (subcutaneous), 50–100 nl (intraventricular) or 10–30 nl (eye specific) of DNA(s) and/or MO solution was injected using an air-pressured injector (Picospritzer II, Intracel). The tip of the capillary was broken with fine forceps under a stereomicroscope so that it released 5–8 nl per pulse. The capillary was removed just before the first electric pulse of the series was delivered by the square wave pulse generator (TSS20 OVODYNE electroporator, Intracel). After the pulse series was completed, the electrodes were removed and the embryo gently collected from the chamber in a large drop of electroporation medium. Electroporated embryos were then placed in sterile 0.1× MBS and grown at 18°C. To avoid damage due to handling, embryos were moved with large round-tip glass tools and were transferred in and out of the chamber with a large plastic pipette. Both the capillary and electrodes were manipulated using manual micromanipulators (Fine Science Tools). Brain Sections, DAPI and TUNEL staining and image processing Embryos were fixed with 4% PFA in PBS over night at 4°C and then rinsed with PBS. Subsequently, fixed embryos were equilibrated in 15% then 30% sucrose/PBS solutions and embedded in Tissue-Tek OCT compound (Sakura). 10 μm cryostat sections were collected on Superfrost slides (VWR) and dried for 60 min prior to staining. Sections were post-fixed in ethanol/acetic acid (2/1 volumes) for 5 min at -20°C prior to TUNEL labeling. TUNEL labeling (Apoptag fluorescein kit S7110, Intergen Company) was performed according to the manufacturer's recommendations. The sections were incubated in DAPI at 1/10000 (D9542, Sigma) for 5 min in 0.1% Triton/1× PBS at room temperature (RT) and washed 3 times in PBS before mounting. Blocking was done with 1% BSA/10% Goat serum/0.1% Triton in 1× PBS for 30 min at RT. For labeling of differentiated neuronal cells, the sections were incubated with anti-acetylated tubulin (6-11B-1, Zymed, stock: 0.5 mg/ml) for 2 h at RT (1/200 in the blocking buffer) and visualized with a Cy3 anti-mouse secondary antibody (AP 124C, Chemicon) (1/1000 in the blocking buffer). Sections were mounted in Fluorosave medium (Calbiochem), and photographed. All images were acquired from grayscale cameras (ORCA-ER, Hamamatsu) using Open lab software (Improvision) and processed in Photoshop (Adobe). For TUNEL quantification, all TUNEL labeling co-localizing with DAPI positive structures in the brain were counted on sections (where the eye was present). The statistical analysis was performed in InStat3 (Graphpad Software Inc). Evaluation of the transfection efficiency For testing the electroporation parameters, embryos from different test conditions were injected with the same volume using the same capillary. Electroporation using the standard setting (20 V/50 ms/1 s/8 x) was always performed at the end of the test series as a control. 12 h after electroporation, the success rate was estimated on live anesthetized embryos under a fluorescence stereoscopic microscope (MZFLII, Leica). Each embryo was scored according to the fluorescence intensity and spread of the signal (0 = no signal, 0.25 = dim, 0.5 = high but restricted, 1 = high and widespread). As absolute efficiency varies with DNA preparations and embryo batches, embryos electroporated with the standard setting were scored first to set the index. Results from different experiments were normalized to the standard settings (100%). The pictures presented and archived were taken under the same conditions (same magnification, time after electroporation and exposure). Embryos exhibiting any apparent damage such as smaller eye, local head depression, defect in eye pigmentation or persistent skin peeling were scored as damaged. The fraction of transfected cells was quantified on serial frontal sections of embryos 6 h, 12 h, 24 h or 48 h after electroporation with nls-GFP. Sections were screened at low power (5×) to identify the rostral most and caudal most positive sections. All inclusive sections were then photographed at 20× (Eclipse 80i, Nikon) using fixed acquisition parameters separately set for the 24 h (for analysis of electroporation kinetics) and 12 h (for analysis of stage and pulse parameters) time points (Orca, Hamamatsu, Open lab, Improvision). Regions of interest (ROIs) corresponding to the hemi-neural tube and superficial regions of the brain were outlined based on DAPI counter-staining and used for subsequent quantification. Thresholds were set for DAPI and GFP fluorescence intensity and the total area in ROIs above threshold was calculated. Thresholds for DAPI and GFP were calibrated so that the ratio of GFP area to DAPI area matched the manual percentage count at 24 h (kinetics) or 12 h (stages and pulse parameters). The centers of mass of DAPI and GFP signals were also calculated. All the quantifications were done in ImageJ (NIH). Morpholino knock-down of GFP expression Embryos were injected separately with: (1) 0.7 μg pCS2GFP or 0.7 μg pCS2GFP+0.33 mM GFPMO (eye and brain); (2) 0.7 μg pCS2GFP+0.1 mM liss-CtrMO, 0.7 μg pCS2GFP+0.33 mM GFPMO+0.1 mM liss-CtrMO, 0.7 μg pEGFPC1+0.1 mM liss-CtrMO or 0.7 μg pEGFPC1+0.33 mM GFPMO+0.1 mM liss-CtrMO (eye); (3) 0.7 μg pCS2GFP+0.7 μg GAP-RFP or 0.7 μg pCS2GFP+0.7 μg GAP-RFP+0.33 mM GFPMO (eye). 12 h after electroporation, images of intact living embryos were acquired and levels of GFP expression were quantified. For the first set of experiments (1), the integral of GFP fluorescence was calculated for the eye region. For the second set (2), a circular ROI encompassing the eye was drawn from the corresponding bright-field pictures and used to determined the mean intensity level of the red (electroporation control) and green (GFP expression) channels. The green to red ratio was calculated for all embryos that exhibited a mean fluorescence intensity over background threshold in the red channel. All acquisitions and quantifications were done blind. In the third set of experiments (3), the expression of GFP and GAP-RFP was measured on serial coronal sections 48 h after electroporation. Images were acquired and thresholds were set identically between the conditions and the GFP/GAP-RFP ratio was calculated. All quantifications were performed in ImageJ and all statistical analysis was done in InStat3 (Graphpad Software Inc). Electroporation of lipofected or electroporated embryos Stage 19–20 eye primordia were lipofected as described previously with GAP-GFP plasmid mixed with DOTAP (Roche) [8]. These lipofected embryos were then electroporated with GAP-RFP at stage 28 as described above. Embryos first electroporated at stage 24 or 28 (GAP-RFP) were allowed to recover at room temperature for several hours before being electroporated at stage 29/30 or 32 (GAP-GFP). Time-lapse in vivo microscopy Electroporation was performed on stage 28 embryos using the standard protocol. When reaching stage 39, embryos were anaesthetized and prepared for live imaging as described previously [64]. Briefly, the eye and skin covering the contralateral brain were removed to expose the transfected axons. The embryo head was placed in 0.05 mg/ml MS222/1× MBS filled chamber formed by a gene frame (ABGene, AB 0576) placed on an oxygen permeable slide (Permanox, Nalgen Nunc, 16005). Only samples with a few isolated axons were selected for subsequent live imaging. Image acquisition was performed on a Nikon Optiphot-2 microscope equipped with a 20× Plan NeoFluar objective and Orca-ER cooled CCD camera (Hammamatsu). To minimize phototoxicity, acquisitions were made with neutral density filters on and short exposure times (50–100 ms). Z-stacks were acquired every 10 min. Cell culture 14 h-20 h after electroporation, brains (fore-, mid-, and hind-brain) and eyes were dissected from electroporated embryos [65] and cut into 2–4 explants. In the case of dissociated primary cultures, tissues from embryos under stage 30 were dissociated in calcium free medium (0.4 mM EDTA) [66] using fire polished Pasteur pipettes. For embryos older than stage 30, their tissues were incubated for 6–8 min in trypsin solution (Gibco) before being mechanically dissociated. The trypsin was inactivated in 10 times its volume of 10% FBS medium prior to trituration. Both explants and dissociated cells were cultured in 60% L15/10% FBS/1% PSF (100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml fungizone; Gibco) on glass coverslips coated with 100 μg/ml poly-L-lysine (Sigma) and 10 μg/ml laminin (Sigma). The cultures were analyzed 24 h and 48 h after plating. Competing interests The author(s) declares that there are no competing interests. Authors' contributions JF designed, performed and analyzed the experiments presented except the in vivo time-lapse imaging which was carried out by JD. JD also participated in establishing the protocol for eye specific transfection and optimized it for later stages. K-M L has made various attempts to load MO in RGCs which led to investigate the potential of electroporation. K-M L provided all control MOs and her expertise in using MO. Both JD and K-M L independently repeated some of the experiments presented. AD, AGR and MP performed pioneer electroporation experiments and AD and MP designed the first set of electrodes. JF drafted the manuscript with inputs from all the authors. CEH contributed to the design and coordination of the study and assisted with the writing of the manuscript. All authors read and approved the final manuscript. Additional file 1 Supplementary Figure 1. Distribution of early GFP-expressing cells in the brain and eye and stage dependency of eye-targeted electroporation. Click here for file(503K, pdf) Additional file 2 Supplementary Figure 2. Potential applications of electroporation to other animal models and projection systems. Click here for file(4.7M, pdf) Additional file 3 Supplementary Methods. Protocol describing the method to create, copy and modify an electroporation chamber. Click here for file(23K, doc) Additional file 4 Supplementary Figure 3. Shapes of the electroporation chambers and electrodes used. Click here for file(308K, pdf) Acknowledgements We thank A. Bowden, S. Cordiner-Lawrie and A. Pungaliya for supplying embryos, I. Pradel for providing the midi preps, M. Perron for the GFP-MO, B. Pownall for the pCS2nls-GFP. We also would like thank F. van Horck for providing the first MO. We are indebted to F. Moret for sharing his electroporation expertise and the electronic and instrumentation service for biological science of the University of Cambridge (Biotronix) for testing the electroporators. We would like to thank R. Seidenfaden, F. Moret, W.A. Harris, D. Maurus, M. Carl, C. Zimmer and L. Poggi for their critical reading of the manuscript; Y. Xue and A. Lin for their dedicated proofreading; L. Strochlic and M. Vitorino for their enthusiasm and comments on the project. This work was funded by a Wellcome Trust Programme Grant (CEH), an EMBO Long-Term Fellowship (JF), a Wellcome Trust studentship (JD), a Croucher Foundation Scholarship (K-M L) and an MCR studentship (AGR). References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
J Neurobiol. 2005 Sep 15; 64(4):405-16.
[J Neurobiol. 2005]Genes Dev. 2003 Jun 15; 17(12):1429-50.
[Genes Dev. 2003]Proc Natl Acad Sci U S A. 2001 Jul 3; 98(14):7869-74.
[Proc Natl Acad Sci U S A. 2001]Dev Dyn. 2005 Feb; 232(2):369-76.
[Dev Dyn. 2005]Methods Cell Biol. 1991; 36():367-87.
[Methods Cell Biol. 1991]Nat Biotechnol. 2003 Jan; 21(1):93-6.
[Nat Biotechnol. 2003]Nat Biotechnol. 1998 Feb; 16(2):168-71.
[Nat Biotechnol. 1998]Nat Cell Biol. 1999 Dec; 1(8):E203-7.
[Nat Cell Biol. 1999]Dev Dyn. 2003 Mar; 226(3):470-7.
[Dev Dyn. 2003]Mol Cell Neurosci. 2004 Jan; 25(1):138-52.
[Mol Cell Neurosci. 2004]FEBS Lett. 2000 Dec 1; 486(1):29-32.
[FEBS Lett. 2000]Differentiation. 2002 Jun; 70(4-5):148-54.
[Differentiation. 2002]Genesis. 2002 Jun; 33(2):81-5.
[Genesis. 2002]Dev Dyn. 2003 Mar; 226(3):470-7.
[Dev Dyn. 2003]Methods. 2001 May; 24(1):43-8.
[Methods. 2001]Biophys J. 2004 May; 86(5):3260-8.
[Biophys J. 2004]Nat Biotechnol. 2003 Jan; 21(1):93-6.
[Nat Biotechnol. 2003]Development. 2005 Oct; 132(20):4483-95.
[Development. 2005]Neuron. 2000 Nov; 28(2):437-47.
[Neuron. 2000]Nature. 2006 Jan 5; 439(7072):31-7.
[Nature. 2006]J Neurobiol. 2002 Nov 15; 53(3):330-42.
[J Neurobiol. 2002]Dev Biol. 2000 Jun 1; 222(1):124-34.
[Dev Biol. 2000]Genesis. 2001 Jul; 30(3):110-3.
[Genesis. 2001]Dev Dyn. 2003 Mar; 226(3):470-7.
[Dev Dyn. 2003]Differentiation. 2002 Jun; 70(4-5):148-54.
[Differentiation. 2002]Development. 2004 Feb; 131(4):851-62.
[Development. 2004]Methods Cell Biol. 2003; 71():339-51.
[Methods Cell Biol. 2003]J Neurosci Methods. 2003 Nov 30; 130(1):65-73.
[J Neurosci Methods. 2003]J Neurosci Methods. 2006 Apr 15; 152(1-2):65-73.
[J Neurosci Methods. 2006]Nat Neurosci. 2006 Oct; 9(10):1247-56.
[Nat Neurosci. 2006]Neural Dev. 2007 Mar 15; 2():6.
[Neural Dev. 2007]Methods. 2006 Jul; 39(3):207-11.
[Methods. 2006]Neuron. 1990 Feb; 4(2):203-14.
[Neuron. 1990]Neuron. 1995 Apr; 14(4):681-4.
[Neuron. 1995]Differentiation. 2002 Jun; 70(4-5):148-54.
[Differentiation. 2002]FEBS Lett. 2000 Dec 1; 486(1):29-32.
[FEBS Lett. 2000]Neuron. 2003 Feb 20; 37(4):597-609.
[Neuron. 2003]J Cell Biol. 2005 Dec 19; 171(6):991-9.
[J Cell Biol. 2005]Methods. 2002 Dec; 28(4):411-9.
[Methods. 2002]Development. 2004 Feb; 131(4):851-62.
[Development. 2004]Development. 2006 Dec; 133(23):4613-7.
[Development. 2006]Development. 2004 Feb; 131(4):851-62.
[Development. 2004]Dev Dyn. 2004 Mar; 229(3):643-50.
[Dev Dyn. 2004]Dev Dyn. 2003 Mar; 226(3):470-7.
[Dev Dyn. 2003]Methods. 2002 Dec; 28(4):411-9.
[Methods. 2002]Development. 2007 Jun; 134(11):2137-46.
[Development. 2007]J Neurosci Res. 1985; 13(1-2):101-22.
[J Neurosci Res. 1985]Neuron. 1992 Aug; 9(2):357-72.
[Neuron. 1992]